BiomX
Latest round
- Series B
Last raised
- Feb 2019
Total raised
- $56M
Investors
- 12
About BiomX
, and Timothy Lu, MD, BiomX Inc. operates as a provider of phage therapy solutions targeting harmful bacteria in chronic diseases for patients with conditions like cystic fibrosis and diabetic foot osteomyelitis. In March 2024, BiomX Inc. The company provides a wide range of phage therapy products to target and eradicate harmful bacteria in chronic diseases such as cystic fibrosis and diabetic foot osteomyelitis. Moreover, the firm develops natural and engineered phage cocktails and customizes phage compositions based on proprietary bacterial targets. Additionally, the company also provides personalized treatments and biomarker discovery services.
Who invested in BiomX
12 investors across 2 rounds
See all investors in BiomX
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about BiomX
Who invested in BiomX?
BiomX has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BiomX raised?
BiomX has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did BiomX last raise money?
BiomX's most recent round on record is a Series B, in Feb 2019.
What does BiomX do?
, and Timothy Lu, MD, BiomX Inc.
Where is BiomX headquartered?
BiomX is headquartered in Ness Ziona, Israel.
Which VCs invest in companies like BiomX?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at BiomX's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like BiomX? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.